Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.61 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.51 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.51 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.49 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RRM1 | P23921 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.46 |
| ▸ | LAP3 | P28838 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10271255 | 1.00 | ZDHHC7 (0.61) | ZDHHC7GNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL15708818 | 1.00 | ZDHHC7 (0.61) | ZDHHC7GNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL9828061 | 1.00 | ZDHHC7 (0.61) | ZDHHC7GNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL20447804 | 1.00 | ZDHHC7 (0.61) | ZDHHC7GNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL22551113 | 1.00 | ZDHHC7 (0.61) | ZDHHC7GNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL22551133 | 1.00 | ZDHHC7 (0.61) | ZDHHC7GNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL5477583 | 1.00 | ZDHHC7 (0.61) | ZDHHC7GNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL16007110 | 1.00 | ZDHHC7 (0.61) | ZDHHC7GNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL5135061 | 1.00 | ZDHHC7 (0.61) | ZDHHC7GNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL29292342 | 1.00 | ZDHHC7 (0.61) | ZDHHC7GNAI3GNAO1GNAI1DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116180088-A | Corrosion inhibitor for aluminum product surface treatment and preparation method thereof | 盐城工学院 | 2023-05-30 | — | — | CN | disclosed |
| US-20210179538-A1 | METHOD FOR PRODUCING 2-OCTYLGLYCINE ESTER HAVING OPTICAL ACTIVITY | AMINOLOGICS CO., LTD. (KR) | 2021-06-17 | — | — | US | disclosed |
| EP-3725766-A1 | METHOD FOR PRODUCING 2-OCTYLGLYCINE ESTER HAVING OPTICAL ACTIVITY | Aminologics Co., Ltd. (KR) | 2020-10-21 | — | — | EP | disclosed |
| EP-3725766-A1 | METHOD FOR PRODUCING 2-OCTYLGLYCINE ESTER HAVING OPTICAL ACTIVITY | Aminologics Co., Ltd. (KR) | 2020-10-21 | — | — | EP | disclosed |
| US-20140256904-A1 | BIOTECHNOLOGICAL SYNTHESIS PROCESS OF OMEGA-FUNCTIONALIZED CARBON ACIDS AND CARBON ACID ESTERS FROM SIMPLE CARBON SOURCES | EVONIK DEGUSSA GMBH (DE) | 2014-09-11 | — | — | US | disclosed |
| US-8476043-B2 | Inhibitors for the soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-02 | — | — | US | disclosed |
| EP-2335701-B1 | Heterocyclic aspartyl protease inhibitors | SCHERING CORP (US) | 2012-07-11 | — | — | EP | disclosed |
| CN-101084216-B | Inhibitors for the soluble epoxide hydrolase | UNIV CALIFORNIA | 2011-09-14 | — | — | CN | disclosed |
| US-20110021448-A1 | Inhibitors for the Soluble Epoxide Hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-27 | — | — | US | disclosed |
| US-20100297023-A1 | Lipid | IMUTHES LIMITED UNIVERSITY OF THE WITWATERSRAND | 2010-11-25 | — | — | US | disclosed |
| US-7662910-B2 | Inhibitors for the soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-02-16 | — | — | US | disclosed |
| EP-2124895-A2 | LIPIDS AND THEIR USE AS NON-VIRAL DELIVERY VEHICLE | IMUTHES LIMITED (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008078102-A2 | LIPIDS AND THEIR USE AS NON-VIRAL DELIVERY VEHICLE | IMUTHES LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
| CN-101084216-A | Inhibitors for the soluble epoxide hydrolase | UNIV CALIFORNIA (US) | 2007-12-05 | — | — | CN | disclosed |
| EP-1814875-A2 | IMPROVED INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE | The Regents of the University of California (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060270609-A1 | Inhibitors for the soluble epoxide hydrolase | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-11-30 | — | — | US | disclosed |
| WO-2006045119-A9 | IMPROVED INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE | UNIV CALIFORNIA (US) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006045119-A2 | IMPROVED INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270609-A1 | Inhibitors for the soluble epoxide hydrolase | EPHX1, EPHX2, NCEH1 | ZDHHC7 320/4885GNAI3 2065/4885GNAO1 1483/4885 |
| US-20110021448-A1 | Inhibitors for the Soluble Epoxide Hydrolase | EPHX1, EPHX2, NCEH1 | ZDHHC7 320/4885GNAI3 2065/4885GNAO1 1483/4885 |
| US-20210179538-A1 | METHOD FOR PRODUCING 2-OCTYLGLYCINE ESTER HAVING OPTICAL ACTIVITY | GNMT, UGT8, OPRM1 | ZDHHC7 160/4885GNAI3 570/4885GNAO1 135/4885 |
| US-20100297023-A1 | Lipid | NR1H2, NR1H3, NR1H4 | ZDHHC7 118/4885GNAI3 2435/4885GNAO1 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.